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Abstract
Cell proliferation has been shown to have multiple functions in development and pattern formation, including roles in growth,
morphogenesis, and gene expression. Previously, we determined that the earliest known morphological event downstream of the male sex
determining gene, Sry, is the induction of proliferation. In this study, we used proliferation inhibitors to block cell division during early
gonad development, at stages before the XY gonad has committed to the testis pathway. Using the expression of sex-specific genes and the
formation of testis morphology as markers of testis determination, we found that proliferation within a specific 8-h window was critical for
the establishment of the male pathway and the formation of the testis. Inhibition of proliferation before or after this critical period led to
smaller gonads, but did not block testis formation. The critical period of proliferation coincides with the initiation of Sry expression and is
essential for the differentiation of Sertoli cells, suggesting that proliferation is a vital component of the initiation of the male pathway by
Sry. We believe these studies suggest that proliferation is involved not only in the elaboration of organ pattern, but also in the choice between
patterns (male and female) in the bipotential gonad.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
In embryonic development, much is known about how
genes and pattern formation initiate and control cellular
processes, such as cell division, migration, and differentia-
tion. However, the reciprocal effect of these cellular pro-
cesses on gene expression and pattern formation is often
overlooked. Studies in a variety of systems indicate that cell
division has a role in many aspects of organogenesis, not
only in mediating growth and shape of organs, but also in
the generation of cell diversity through asymmetric divi-
sion, the timing of biological clocks, and the regulation of
distances between signaling centers (Horvitz and Herskow-
itz, 1992; Pourquie, 1998; Tabin, 1998). It has been theo-
rized that, for some cell types, the process of DNA replica-
tion remodels chromatin structure and allows access to
previously inactive regulatory domains, thereby changing
the expression patterns of specific genes in dividing cells
(Holtzer et al., 1975, 1983).
In support of this theory, inhibition of cell proliferation
in many systems has been shown to block differentiation of
specific cell types and change the expression of some genes.
Studies in the developing limb have shown that cell division
and pattern formation are functionally integrated, as alter-
ations in pattern formation affect regions of proliferation
and, reciprocally, alterations in proliferation and cell cycle
lengths affect pattern formation (French et al., 1976; Bryant
and Gardiner, 1992; Ohsugi et al., 1997; Schaller et al.,
2001). Many key molecules in the limb, such as SHH,
FGFs, BMPs, and RA, are involved in both outgrowth and
pattern formation and may provide links between the regu-
lation of proliferation and limb morphogenesis. In support
of these ideas, inhibition of cell proliferation in the limb by
various mechanisms has been shown to cause alterations in
gene expression and leads to diverse effects on limb mor-
phology, such as supernumerary digits or the loss of prox-
imal elements (Stephens, 1988; Ohsugi et al., 1997).
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Studies in another system, the early gonad, have sug-
gested that proliferation and related organ growth may
not only be involved in the acquisition and elaboration of
organ pattern, but also in the choice between patterns
(male and female) in the bipotential gonad. In the mouse,
the gonad forms at 10.0 days postcoitum (dpc) as a ridge
of cells on the ventromedial surface of the mesonephros.
Initially, the gonad is morphologically identical in both
sexes and is considered bipotential, as it can be induced
to become either a testis or an ovary. Early studies in
several mammalian species suggested that the choice
between testis and ovarian patterns in the gonad was
potentially controlled by cell proliferation and gonad
growth. At equivalent gestational ages, it was observed
that, on average, male embryos are more developmen-
tally advanced than females (Scott and Holson, 1977;
Pedersen, 1980; Seller and Perkins-Cole, 1987). This
difference between the sexes precedes the formation of
the gonad and led to the hypothesis that growth rate may
influence the sex of the embryo. The observation that the
early male gonad is larger than the female gonad in many
vertebrates supported the view that the differential
growth rate between the sexes somehow determined the
sex of the gonad, such that gonads with more rapid
growth rates became testes, while gonads which failed to
reach a certain size by a given stage developed into
ovaries (Mittwoch, 1969, 1989; Mittwoch and Buehr,
1973; Hunt and Mittwoch, 1987). However, many studies
comparing gonad size between the sexes did not take into
account the accelerated development of male versus fe-
male embryos. Additionally, the more rapid growth rate
of male embryos is not an absolute distinction: some
male embryos are smaller and develop more slowly than
their female littermates, suggesting that growth rate
and/or developmental acceleration are not the primary
determinants of the sex of the embryo.
In the 1990s, it was discovered that sex is genetically
determined in mammals by the presence or absence of a
single gene on the Y chromosome, Sry (Gubbay et al., 1990;
Lovell-Badge and Robertson, 1990). Expression of this
gene is sufficient to initiate the testis pathway in XX gonads
(Koopman et al., 1991; Eicher et al., 1995), thereby over-
riding any bias of the smaller XX gonads for the ovarian
pathway. Additionally, it has been shown that the acceler-
ation of development in postimplantation male embryos is
an effect of the X chromosome constitution, not the Y
chromosome, and therefore is not the primary sex-determin-
ing mechanism (Thornhill and Burgoyne, 1993; Burgoyne
et al., 1995, 2001). However, as we have shown previously,
one of the earliest effects of Sry expression is an increase in
cell proliferation (Schmahl et al., 2000). A corresponding
increase in the size of the male gonad is also observed
within 24 h of the peak of Sry expression. Thus, prolifera-
tion and differential growth rates may yet have an important
role in testis formation and sex determination downstream
of Sry.
In this study, we used proliferation inhibitors both in
vivo and in culture to investigate whether cell proliferation
is necessary for aspects of sex determination and the devel-
opment of the testis. We show that a specific 8-h period of
early proliferation is necessary for the differentiation of
male-specific cell types, the expression of male-specific
genes, and the formation of testis morphology. This period
occurs within hours of the initiation of Sry expression,
suggesting that proliferation within this period is an early
part of the mechanism by which Sry initiates the male
pathway.
Materials and methods
Proliferation inhibition in staged prenatal gonads
Timed matings were produced by housing CD-1 female
mice with males of the same strain overnight and checking
for vaginal plugs. Noon on the day a vaginal plug was
recorded was considered 0.5 days postcoitum (dpc). To
reduce variability in the age of the embryos, most matings
set up for the injection of proliferation inhibitors were set up
for a short period of time (between 9 PM and 2 AM).
5-Flurouracil (5-FU; 30 mg/kg) or methotrexate (MTX; 40
mg/kg) was administered by intraperitoneal injection into
pregnant females between 10.5 and 11.5 dpc, at the times
indicated in Table 1. Three to five pregnant mice were
injected at each time point to achieve a minimum of 15 XY
embryos per time point. The litters of these injected mice
were dissected at 12.5 dpc (or later as indicated), the gonads
were removed from each embryo, and the presence or ab-
sence of testis cords was noted using a dissecting micro-
scope (Leica MZFLIII). The sex of these embryos was
determined by staining of X chromatin Barr bodies in the
amniotic sac (Palmer and Burgoyne, 1991). An embryo that
was XY by amniotic staining but had no visible testis cords
was considered a cordless XY (Table 1). The percent cord-
less XY was calculated for each litter, and the mean cordless
XY was calculated for each time point by averaging the
percent cordless XY from each litter within that time point.
The appearance of litters and individual embryos within
each litter injected with 5-FU varied (see Results for de-
scription). Some litters had severely affected individuals,
with many large or burst blood vessels, the presence of
blood within the body cavity, and large, fluid-filled edemas
in the head, body, and limbs. The organs of these individ-
uals were much smaller than normal and exhibited signs of
deterioration, such as many loose cells and a rough appear-
ance. Gonads were not dissected form these embryos. In-
stead, these embryos were classified as severely affected,
and the number of severely affected embryos was added to
the number of dead or reabsorbed individuals in each litter,
divided by the total number of embryos in the litter and
recorded as percent lethality in Table 1.
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Table 1A
Inhibition of proliferation at a specific stage blocks testis cord formation (10.5–11.0 dpc)
Time 5-FU Inja Condition of litterb % lethality Total XY # Cord-less XY % Cord-less XY
1–2 PM (10.5 dpc) mild-mod 0% 4 0 0%
mod-sev 25.0% 5 0 0%
mod-sev 54.5% 1 0 0%
mod-sev 78.6% 3 0 0%
mod-sev 78.6% 2 0 0%
47.3  17.2%c 15d 0d 0%c
2–3 PM mod 0% 5 0 0%
mod 14.3% 6 0 0%
mod-sev 20.0% 5 0 0%
mod-sev 40.0% 3 0 0%
18.6  9.6% 19 0 0%
3–4 PM mod-sev 10.0% 5 0 0%
mod-sev 18.2% 5 0 0%
mod-sev 25.0% 7 0 0%
17.7  5.3% 17 0 0%
4–5 PM mild 0.0 7 0 0%
mod-sev 33.3 4 0 0%
mod-sev 44.4 3 0 0%
mod-sev 78.6 1 0 0%
39.1  18.7% 15 0 0%
5–6 PM mild nd 7 0 0%
mod 0% 3 0 0%
mod-sev 17% 5 0 0%
8.3  11.8% 15 0 0%
6–7 PM mild nd 3 0 0%
mild 9.1 6 0 0%
mod 0.0% 7 0 0%
4.5  6.4% 16 0 0%
7–8 PM mod 7.7% 4 0 0%
mod 14.3% 3 0 0%
mod 27.7% 3 0 0%
mod-sev 33% 5 0 0%
20.7  6.8% 15 0 0%
8–9 PM mild nd 6 3 50.0%
mild 0.0% 8 3 37.5%
mod-sev 8.3% 5 2 40.0%
mod-sev 16.7% 7 0 0.0%
8.3  5.9% 26 8 31.9  12.7%
9–10 mild 0% 7 2 28.6%
mild 9% 6 4 66.7%
mod 7% 6 0 0.0%
5.4  3.4% 19 6 31.8  23.6%
10–11 PM mild 7.7% 5 0 0.0%
mod nd 4 3 75.0%
mod-sev 16.7% 5 5 100.0%
mod-sev 33.3% 5 5 100.0%
19.2  9.2% 19 13 68.8  27.3%
11–12 PM (11.0 dpc) mild 20.0% 5 2 40%
mod 0.0% 6 0 0.0%
mod-sev 0.0% 3 2 66.7%
mod-sev 33.3% 1 0 0.0%
13.3  9.4% 15 4 26.7  32.6%
a Injections of the proliferation inhibitor 5-FU were administered to pregnant females between 10.5 and 11.0 dpc at the times indicated.
b Embryos were dissected at 12.5 dpc and the condition of the litter was noted. See text for description of mild, moderate (mod), and severely (sev) affected.
c Mean for that time point,  SEM.
d Total for that time point.
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Table 1B
Inhibition of proliferation at a specific stage blocks testis cord formation (11.0–11.5 dpc)
Time 5-FU Inja Condition of litterb % lethality Total XY # Cord-less XY % Cord-less XY
12–1 AM (11.0 dpc) mild nd 4 0 0.0%
mod nd 8 4 50.0%
mod 0.0% 9 1 11.1%
mod 9.1% 6 2 33.3%
mod-sev 15.4% 6 1 16.7%
8.1  5.5%c 33d 8d 22.2  9.8%c
1–2 AM mild 0.0% 9 0 0.0%
mild 7.7% 8 1 12.5%
mild 14.3% 5 1 20%
7.3  5.1% 22 2 10.8  7.1%
2–3 AM mod 0.0% 7 0 0.0%
mod 0.0% 6 0 0.0%
mod 16.7% 5 1 20.0%
5.6  6.8% 18 1 6.7  8.2%
3–4 AM mild 14.3% 7 0 0%
mod 14.3% 5 0 0%
mod 27.3% 4 2 50%
18.6  5.3% 16 2 16.7  20.4%
4–5 AM mild 0.0% 5 0 0%
mild 7.7% 3 0 0%
mod 0.0% 3 0 0%
mod-sev 0.0% 5 0 0%
1.9  2.2% 16 0 0%
5–6 AM mild 0.0% 5 0 0%
mod 0.0% 8 0 0%
mod 8.3% 7 0 0%
2.8  3.4% 20 0 0%
6–7 AM mild 7.7% 7 0 0%
mild-mod 0.0% 4 0 0%
mild-mod 0.0% 5 0 0%
2.6  3.1% 16 0 0%
7–8 AM mild 11.1% 5 0 0%
mild-mod 0% 4 0 0%
mod 10.0% 6 0 0%
7.0  4.3% 11 0 0%
8–9 AM mild 0.0% 8 0 0%
mild 7.1% 8 0 0%
mild-mod 0.0% 2 0 0%
2.4  2.8% 18 0 0%
9–10 AM mild 0.0% 6 0 0%
mild-mod 10% 2 0 0%
mod 0.0% 7 0 0%
3.3  4.1% 15 0 0%
10–11 AM mild 0.0% 8 0 0%
mild 0.0% 9 0 0%
mild 6.7% 6 0 0%
2.2  2.7% 23 0 0%
11–12 AM (11.5 dpc) mild 0.0% 4 0 0%
mild nd 3 0 0%
mod nd 3 0 0%
nd nd 8 0 0%
0.0% 18 0 0%
a Injections of the proliferation inhibitor 5-FU were administered to pregnant females between 11.0 and 11.5 dpc at the times indicated.
b Embryos were dissected at 12.5 dpc and the condition of the litter was noted. See text for description of mild, moderate (mod), and severely (sev) affected.
c Mean for that time point,  SEM.
d Total for that time point.
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The time course of proliferation inhibition and apoptosis
in vivo
To determine the time course of proliferation inhibition, we
injected pregnant mice with 30 mg/kg 5-FU at 10:30 PM on
the 10th day postcoitum and dissected litters 2, 4, 14, or 24 h
after injection. Gonads were removed from half of the XY
embryos in these litters, and dividing cells were detected by
using a 1:500 dilution of a rabbit polyclonal antibody against
phospho-Histone H3 (Upstate #06-570). Germ cells and vas-
culature were visualized by using a 1:200 dilution of a rat IgG
antibody against mouse platelet endothelial cell adhesion mol-
ecule (PECAM; Pharmagen, cat. #553370). For immunofluo-
rescence, XY gonads from each time point were pooled, fixed
in 4% paraformaldehyde overnight, rinsed three times in PBS,
incubated for 1 h at room temperature in 10% goat serum,
0.01% Triton X-100 in PBS, incubated overnight at 4°C in
primary antibodies diluted in 1% goat serum, 0.01% Triton
X-100, and then rinsed three times in PBS. The samples were
incubated in 1:1000 dilutions of the appropriate secondary
antibodies overnight (rhodamine-conjugated anti-rat IgG and
fluorescein-conjugated anti-rabbit from Jackson ImmunoRe-
search), rinsed three times in PBS, and mounted for whole-
mount confocal imaging as described in Karl and Capel
(1998).
To determine whether 5-FU treatment caused an increase
in apoptosis in the gonad, the remaining XY embryos from
the above 5-FU time course were treated with the vital
lysosomal dye, LysoTracker Red (Molecular Probes, OR),
using a protocol modified from Zucker et al. (1999). Briefly,
3 l of LysoTracker Red was added to 1 ml of DMEM with
10% fetal calf serum and 5% CO2. Embryos were incubated
in this labeling media for 30 min at 37°C. After labeling,
embryos were washed three times in PBS, then three times
in PBS containing 0.1% Tween 20 for 30 min each wash.
These samples were fixed in 4% paraformaldehyde, embed-
ded in 20% PBS:OCT, and cryosectioned. Sections were
blocked in 10% goat serum, 0.1% Triton X-100 in PBS, and
incubated with primary and secondary antibodies by using
the protocol described above. Laminin was detected with a
rabbit polyclonal antibody generously donated by Harold
Erickson.
Fig. 1. Inhibition of proliferation at specific stages can block testis cord formation and alter the expression of male-specific genes. Testis cords are visible
in normal XY gonads dissected at 12.5 dpc (the gonad is pictured on top of the attached mesonephros). At this stage, XY gonads express the male-specific
genes Sox9 and Mis within testis cords (column A). Cords are not visible in the XX gonad. During most stages, injection of a proliferation inhibitor (5-FU)
into pregnant females led to smaller gonads, but XY gonads still formed testis cords and expressed Sox9 (XY gonads in column B, D). However, when
proliferation was blocked between 10.8 and 11.2 dpc (indicated by red box on timeline), many of the XY gonads did not form cords and did not express
normal levels of Sox9 or Mis (column C). Scale bar indicates 250 M.
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Fig. 2. Graph of the percent cordless XY gonads observed per litter versus the time of 5-FU injection. Injection of a proliferation inhibitor (5-FU) into pregnant
females between 8 PM on the 10th gestational day and 4 AM on the 11th gestational day (10.8–11.2 dpc) blocked testis cord formation in a percentage of
XY gonads (red bars). Gray lines indicate SEM. Injection of 5-FU before or after this period did not block cord formation.
Fig. 3. Timeline of proliferation inhibition and apoptosis in vivo. Dividing somatic cells (green in A–E) are concentrated at the surface of the male gonad
between 10.5 and 11.0 dpc. Some germ cells and vascular cells (red) also divide during this period (A). 5-FU blocks most cell division in the genital ridge
within 2 h of injection (B). Cell division resumes between 4 and 14 h after injection (C, D) and is observed in somatic and germ cells through at least 24 h
after injection (E). In (A–E), the gonad and attached mesonephros was disected and viewed by using a 10 lens. Sagittal confocal sections of the gonad at
higher magnification (40) are shown below. Apoptosis (green in F–J) was examined in transverse sections of male embryos. In these sections, an antibody
against laminin was used to visualize embryo structures (blue in F–J). Apoptotic cells are normally observed in and associated with the mesoneprhic duct
(md) and tubules (tub) of the mesonephros (outlined in F–J). In the gonad (above the dashed line), few apoptotic cells were observed at this stage. After 5-FU
injection, apoptosis does not substantially increase in the gonad and few apoptotic cells were observed even 14 (I) or 24 h (J) after injection. Scale bars
indicate 100 M.
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Proliferation inhibition in culture
To block proliferation in culture, gonads were removed
from embryos between 11.0 and 11.5 dpc and cultured in
shallow grooves on agar blocks as previously described
(Martineau et al., 1997). Affi-gel blue beads (Biorad) were
absorbed in a 10-g/ml solution of aphidicolin in PBS, or a
control of PBS for 1 h at room temperature. Two to three
beads were then cultured adjacent to XX or XY gonads for
36–48 h. The gonads were fixed in 4% paraformaldehyde
and processed for in situ hybridization as previously de-
scribed (Henrique et al., 1995). The in situ probe for Sox9
was provided by Peter Koopman (Kent et al., 1996), the
probe for Mis was provided by Robin Lovell-Badge, and the
probe for Dax-1 was provided by Amanda Swain (Swain et
al., 1996). To determine the extent of proliferation inhibi-
tion with aphidicolin beads, gonads were cultured for 12 h
as above, with affi-gel blue beads absorbed with aphidicolin
or PBS, in media containing 10 M 5 bromo-2-deoxy-
uridine (BrdU). BrdU is a thymidine analog that is incor-
porated into the DNA of dividing cells and will label cells
that pass through S-phase during this 12-h labeling period.
Gonads were fixed after 12 h in 4% paraformaldehyde, and
BrdU was detected with an antibody as described in
Schmahl et al. (2000). To determine the affects of aphidi-
colin on gonad morphology, somatic cells were detected
with a 1:200 dilution of an antibody against steroidogenic
factor 1 (SF1), a rabbit polyclonal antibody donated by
Ken-ichirou Morohashi. Germ cells and vasuclature were
detected with an antibody against PECAM.
Results
Blocking proliferation at specific stages blocks cord
formation
To investigate the role of proliferation in gonad organo-
genesis, we administered an intraperitoneal injection of 30
mg/kg of the proliferation inhibitor 5-FU to staged pregnant
mice during the early, bipotential stages of gonad formation
(between 10.5 and 11.5 dpc). This timeline includes stages
just before the initiation of Sry expression, through the first
signs of male morphology and differentiation. Gonads in-
jected with proliferation inhibitor were dissected after testis
morphology is normally apparent (12.5 dpc). At this stage,
testis cords are visible using a light microscope and consist
of groups of germ cells surrounded by a layer of Sertoli cells
(male-specific cells that act as supporting cells for the germ
cells), covered by a thick basal lamina. As expected, the
gonads of both sexes were much smaller than controls after
the injection of a proliferation inhibitor (Fig. 1), linking a
size increase of both the ovary and the testis to proliferation.
However, when proliferation was blocked between 8 PM on
the 10th gestational day and 4 AM on the 11th gestational
day, many of the XY gonads in each litter did not develop
testis cords (Figs. 1C and 2; Table 1A and B). Inhibition of
proliferation before or after this critical period led to smaller
testes and reduced numbers of cords, but did not completely
block testis cord formation.
A large amount of variation in the percentage of cordless
gonads was recorded at each time point. This was probably
due to variation in the exact stage of each litter and the
individuals within the litter at the time of injection, as litters
could only be staged based on the assumption that mating
occurred at midnight on the day of the post coital plug. Most
matings were set up for only 5 h (between 9 PM and 2 AM)
to reduce variability in the age of the embryos; however,
differences in the time of ovulation may also affect the time
of conception. As the window of cordless gonads is small,
even a 5-h difference in the stage of the litter could put it
outside of the window of susceptibility. More accurate ways
of staging the litter (such as counting tail somites) could not
be done on the day of injection since the embryos were not
sacrificed for several days. Proliferation inhibitors affected
tail somite numbers on the day of dissection. Despite this
inability to exactly stage the embryos, cordless gonads were
not observed when injected before 8 PM on the 10th ges-
tational day (Table 1A), or after 4 AM on the 11th gesta-
tional day (Table 1B), indicating that the ability of prolif-
eration inhibitors to block cord formation is restricted to a
stage within this 8-h period.
To determine the concentration of 5-FU needed to block
cord formation, we tested a range of doses for each inhib-
itor. Previous studies in pregnant mice or rats at similar
stages show a decrease in fetal weight, an accumulation of
cells in S-phase, and decrease of DNA synthesis between
doses of 20 and 40 mg/kg 5-FU, with malformations and
percent lethality increasing as the dose increases (Skalko
and Jacobs, 1978; Elstein et al., 1993; Shuey et al., 1994).
We tested concentrations of 5-FU within and above this
range (20, 30, 40, and 50 mg/kg). A dose of 50 mg/kg 5-FU
resulted in 100% lethality by 13.5 dpc. Doses of both 30 and
40 mg/kg 5-FU blocked cord formation when injected be-
tween 8 PM on the 10th gestational day and 4 AM on the
11th gestational day. We choose to use the lower dose (30
mg/kg) in this study due to its higher survival rate and less
severe effects on embryo morphology. Doses of 20 mg/kg at
8 PM and midnight on the 10th day of gestation did not
affect cord formation, but a complete time course was not
done for this concentration.
The block of cord formation seen in 5-FU-treated mice is
due to the inhibition of cell proliferation
To verify that 5-FU blocks cell division and to determine
the time course of this block, we injected 30 mg/kg 5-FU
into pregnant mice at 11 PM on the 10th day postcoitum.
Litters were dissected 2, 4, 14, or 24 h after injection, and
dividing cells were detected by using an antibody against
the mitotic marker phospho-Histone H3 (Hendzel et al.,
1997). In controls during this period, this antibody detects a
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population of dividing cells at the surface of the male gonad
(Fig. 3A). Within 2 h of 5-FU injection, a loss of cell
proliferation was observed in the gonad and the adjacent
mesonephros (Fig. 3B). This inhibition of proliferation con-
tinued for at least 4 h after injection. Between 4 and 14 h
after injection, cell proliferation resumed in the embryo, and
dividing cells (both somatic and germ cells) were once
again observed in the gonad (Fig. 3C–E).
5-FU can induce either cell cycle arrest or apoptosis in
dividing cells. This apoptosis occurs via a process known as
“thymineless death” and is generally observed within 12–24
h after 5-FU treatment. Studies have shown that the sensi-
tivity to thymineless death varies in different cell types and
tissues and is dependent on many factors, including the cell
cycle stage, bcl/bax ratio, microenvironment, and quantity
of 5-FU administered (Houghton and Houghton, 1996; Mir-
jolet et al., 2000; Inomata et al., 2002). To determine
whether 5-FU induces apoptosis in the gonad, we used the
vital lysosomal dye, LysoTracker Red. In control embryos
not injected with 5-FU, LysoTracker Red detected apoptosis
in and associated with the mesonephric tubules (tub) and
duct (md; outlined in Fig. 3F–J). This pattern of apoptosis is
consistent with the known degradation and remodeling of
these structures during this period, which eventually leads to
the formation of the epididymus in the male (Smith and
Mckay, 1991). In the gonads of control embryos, a few
(1–3) apoptotic cells were observed per section (arrow in
Fig. 3F). These cells were often, but not always, found near
the boundary of the gonad and mesonephros (dashed line).
Following 5-FU injection, LysoTracker Red detected an
increase in the number of apoptotic cells in other tissues,
particularly in and around the somites, and limb buds 14 and
24 h after injection (data not shown). However, in the
mesonephros, the number of apoptotic cells actually ap-
peared to decrease overtime (Fig. 3G–J). This was presum-
ably due to the normal progressive loss of the tubules from
all but the caudal portions of the mesonephros during this
phase in development. In the gonad, few apoptotic cells
were observed even up to 14 or 24 h after 5-FU injection,
with roughly one to three labeled cells observed per section.
As in control gonads, these cells were frequently associated
with the mesonephric boundary, and no concentrations of
apoptotic cells or areas of intense staining were observed in
the gonad itself, indicating that this concentration of 5-FU
does not induce apoptosis in this tissue at this time.
5-FU is a pyrimidine analogue that is known to inhibit
thymidylate synthase, a key enzyme in the production of
dTTP (Santi et al., 1974; Christopherson and Lyons, 1990).
This results in the inhibition of DNA synthesis. However,
5-FU has been shown to have effects other than the inhibi-
tion of DNA replication. Problems in pre-mRNA synthesis,
splicing, and translation have been observed in 5-FU-treated
cells, possibly due to the incorporation of 5-FU into pre-
mRNA or a more direct inactivation of components of
splicing machinery (Heidelberger et al., 1983; Ghoshal and
Jacob, 1997). To verify that the block of cord formation
seen in 5-FU-treated mice was due to the inhibition of
proliferation and not other effects of 5-FU, we injected mice
with another proliferation inhibitor, methotrexate (MTX).
MTX also blocks cell division through the decrease of dTTP
production. However, MTX is a folic acid analog and a
potent inhibitor of a different enzyme in the thymidylate
synthesis pathway (dihydrofolate reductase; reviewed in
Genestier et al., 2000). The cytotoxic and differentiating
effects of MTX can be prevented by the addition of thymi-
dine (Burres and Cass, 1987; Schwartz et al., 1992; O’Neill,
1998), suggesting that the effects of MTX are specific to the
inhibition of de novo thymidylate synthesis and DNA rep-
lication. Previous studies indicated that doses of MTX be-
tween 20 and 50 mg/kg were likely to affect proliferation in
the embryo (Skalko and Gold, 1974; Darab et al., 1987). We
tested doses within and above this range (20, 30, 40, and 60
mg/kg). Doses of 20 and 30 mg/kg resulted in no visible
effects on embryo development by 14.5 dpc and did not
appear to affect cord formation. At doses of 40 and 60
mg/kg MTX, some malformations of the embryo were ob-
served and cord formation was inhibited within the sensitive
period in some gonads. (Fig. 4A and B), supporting the
theory that the loss of testis cords is due to the inhibition of
cell proliferation and the loss of dividing cells in the early
gonad.
The ability of the proliferation inhibitor to block cord
formation did not correspond to the severity of the
malformations induced by the inhibition
Litters (and individual embryos within each litter) ex-
posed to proliferation inhibitors varied in their general ap-
pearance. Some litters showed very few ill effects, beyond
a shortening of the limbs and tail. These litters generally had
low lethality (ranging from 0 to 14.3%) and were classified
as mild in Table 1. Many litters showed more characteristics
of proliferation inhibition, such as a much shorter or kinked
tail, cranial/facial abnormalities, small edemas in the mid-
brain, and a few swollen or burst blood vessels. These litters
exhibited higher lethality (0– 33.3%) and were classified as
moderately affected (mod) in Table 1. Litters that had a mix
of appearances between moderate and more severely af-
fected were also observed and classified as mod-sev in
Table 1. (Gonads from the most severely affected individ-
uals were eliminated from the study, see materials and
methods for description.) Mod-sev litters had a higher range
of lethality (0–78.6%).
Litters with mildly affected appearances were more
likely to result from 5-FU injections at later time points,
while mod-sev litters generally, but not exclusively, resulted
from 5-FU injections during the first 12-h range of this
study (10.5–11.0 dpc). This difference in the severity of the
general effects of 5-FU injection could be due to the differ-
ence in the time that these litters were allowed to develop
after injection. (For example, litters injected at noon on 10.5
dpc developed for 48 h before dissection at 12.5 dpc, while
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Fig. 4. Cordless XY gonads are observed at later stages. The proliferation inhibitors 5-FU and MTX were injected into pregnant mice during the sensitive
period (8 PM and 10 PM, respectively), then dissected at 14.5 dpc. As observed in litters dissected at 12.5 dpc, both XY gonads with cords (A, D) and XY
cordless gonads (B, E) were observed at 14.5 dpc. Cords were detected by using light microscopy (A–C) and Sox9 expression (D–F). Scale bar indicates 250
M.
Fig. 5. Inhibiting proliferation in culture alters the expression of sex-specific genes. Gonads were dissected between 11.0 and 11.5 dpc and cultured 36 h with
beads treated with PBS or the proliferation inhibitor, aphidicolin (gonad with bead shown in A). Using BrdU to label all dividing cells within a 12-h period,
we observed that proliferation was reduced under the aphidicolin-treated bead and in the gonad as a whole (dividing cells are red in B and C). Most somatic
cells were detected with an antibody against SF1 (green), and germ cells and vasculature were detected with an antibody against PECAM (blue). Using in
situ hybridization to determine the expression of sex-specific genes in XY gonads, it was observed that aphidicolin-treated beads reduced the expression of
the male-specific gene Sox9 expression under the area of the bead (H) and induced or maintained expression of the female-specific gene, Dax1 (J). In XX
gonads, aphidicolin did not affect the expression of Sox9 (I) or Dax1 (K). The black scale bar indicates 250 M in D–K.
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litters injected at noon on 11.5 dpc developed for only 24 h
before dissection at 12.5 dpc.) However, litters injected
during the last 12 h (11.0–11.5 dpc) and dissected 48 or
even 72 h later (at 13.5 and 14.5 dpc) still showed a mild
appearance. This suggests that the difference in the general
effects of the proliferation inhibitors is linked to the sensi-
tivity of the stage of the litter, not the length of the interval
between injection and dissection, an effect well documented
with teratogens during pregnancy (Persaud et al., 1985).
Cordless XY gonads were observed in all classifications of
litters (mild, mod, and mod-sev; see Table 1A and B), and
a Chi-squared test indicated that there was no significant
difference between any of the classifications in the percent
of cordless XY gonads during the sensitive period (2 
1.53, P  0.45). Thus, the ability of the proliferation inhib-
itor to block cord formation was not dependent on the
severity of the general effects of the proliferation inhibitor.
The expression of male-specific genes is altered when
cord formation is blocked by proliferation inhibitors
The expression of male-specific genes was investigated
in gonads treated with proliferation inhibitors. Under nor-
mal conditions, Sox9 and Mis have sex-specific expression
patterns at 12.5 dpc and are detected in XY gonads, not XX
gonads. At this stage, Sox9 and Mis are expressed within
Sertoli cells in the testis cords and are considered hallmarks
of Sertoli differentiation. In XY gonads that appeared cord-
less after exposure to proliferation inhibitors, the expression
of both Sox9 and Mis was abnormally localized, reduced, or
even absent (Fig. 1C), indicating that Sertoli differentiation
is also disrupted in these gonads. Like the block of cord
formation, this effect on gene expression was stage-depen-
dent. Inhibition of proliferation outside the critical period
(before 8 PM or after 4 AM) did not affect the expression
pattern of these genes. Interestingly, when Sox9 and Mis
were detected in cordless XY gonads, they were invariably
detected most strongly at the anterior of the gonad.
To determine whether the block of cord formation and
male-specific gene expression seen in cordless XY gonads
at 12.5 dpc is due to a permanent alteration of the male
pathway, or merely a delay in testis formation, we examined
gonads from litters dissected at a latter stage. At 14.5 dpc,
2 days after cord formation is normally visible by light
microscopy, litters injected with 5-FU or MTX during the
critical period still showed both corded (Fig. 4A and D) and
cordless (Fig. 4B and E) XY gonads. Sox9 expression was
absent in cordless XY gonads at this stage as well (Fig. 4E),
indicating that injection of proliferation inhibitors at earlier
stages produces a long-lasting block of cord formation and
Sertoli differentiation.
We also used aphidicolin-treated beads to inhibit prolif-
eration in cultured gonads. Using BrdU to label proliferat-
ing cells over a 12-h period, it was observed that aphidico-
lin-treated beads blocked proliferation under the bead (see
Fig. 5B and C). In cultured XY gonads, Sox9 expression is
normally associated with areas of cord formation, and this
expression was not disrupted by culture with control beads
(Fig. 5D). However, when XY gonads were cultured with
aphidicolin-treated beads, the extent of Sox9 expression was
Fig. 6. Stages of testis development. Sry (light blue) is expressed between roughly 10.5 and 12.4 dpc (Hacker et al., 1995). Testis cords (purple) become
apparent between 12.0 and 12.5 dpc. BrdU pulse-chase studies have indicated that pre-Sertoli cells (light green) proliferate between 10.5 and 11.5 dpc
(Schmahl et al., 2000). Pre-Sertoli cells cease proliferation after 11.5 dpc. Sertoli cell proliferation resumes after 12.0, when dividing Sertoli cells are observed
within the nascent cords. Blocking experiments in this study have identified a stage of proliferation (red) that appears to be critical for testis cord formation
and Sertoli differentiation. This stage is between 10.8 and 11.2 dpc, just before BrdU labeling detects the beginnings of a wave of male-specific proliferation
(yellow), and is coincident with the early proliferation of pre-Sertoli cells.
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decreased in the gonad as a whole, and nearly eliminated
from the area under the bead (Fig. 5H), suggesting that
proliferation inhibition blocked the differentiation of Sertoli
cells in this region of the gonad.
Another gene with a sex-specific expression pattern,
Dax1, is expressed in both XX and XY gonads before sex
determination, but is downregulated in XY gonads by 12.5
dpc, and its expression becomes specific to XX gonads
(Swain et al., 1998). Dax1 was not observed in XY gonads
cultured with control beads (Fig. 5F). However, when XY
gonads were cultured with beads soaked in aphidicolin,
Dax1 expression was observed (Fig. 5J), indicating that the
reduction of proliferation induced or maintained the expres-
sion of this female-specific gene in the XY gonad. Interest-
ingly, Dax1 was not upregulated specifically in the area
under the bead, and its expression was more uniform than
Sox9 repression. Using BrdU labeling, it was observed that
aphidicolin-treated beads decreased proliferation in the go-
nad as a whole, not just under the bead (Fig. 5B and C).
Thus, the expression of Dax1 in the XY gonad may be an
effect of an overall decrease of proliferation in the gonad.
Aphidicolin beads had no effect on the expression of Sox9
(Fig. 5E and I) or Dax1 (Fig. 5G and K) in cultured XX
gonads.
Discussion
The mammalian sex-determining gene, Sry, is expressed
in the XY gonad during a very short period of time (less
than 48 h in the mouse; Hacker et al., 1995), yet during this
period, it initiates a cascade of events that divert the devel-
opment of the early gonad from the ovarian to the testis
pathway. One of the first morphological changes initiated
by Sry is an increase in the size of the XY gonad. This
increase in size is due at least in part to an increase in cell
proliferation in the XY gonad that is not observed in the XX
gonad. This male-specific increase in proliferation is ob-
served before any other morphological changes in the testis
pathway (such as the formation of testis cords) and occurs in
at least two stages, with pre-Sertoli cells (the cell type that
expresses Sry) proliferating during the first stage, but not the
second (Karl and Capel, 1998; Schmahl et al., 2000). Using
XX/Sry transgenic mice, it has been shown that the prolif-
eration increase is dependent on Sry and independent of
other genetic differences between the sexes (such as X
chromosome dosage, or other genes on the Y chromosome).
A specific stage of proliferation is necessary for the
establishment of the testis pathway
In this study, we used proliferation inhibitors both in
vivo and in culture to investigate the function of prolifera-
tion in the establishment of the testis pathway. We have
shown that inhibition of proliferation during a specific 8-h
period of gonad development blocked the formation of testis
cords, and reduced or blocked the expression of male-
specific genes in XY gonads. Proliferation inhibition also
increased or maintained the expression of a female-specific
gene (Dax1) in the male, yet did not affect Dax1 expression
in the female. Thus, proliferation is not only necessary for
elements of the male pathway, but may also be involved in
the inhibition of the female pathway in the XY gonad.
Inhibiting proliferation before or after this 8-h period did
not block cord formation or male-specific gene expression,
indicating that only this specific stage of proliferation is
essential for aspects of male pattern formation. The critical
period of proliferation corresponds to roughly 10.8 through
11.2 dpc (Fig. 6) and coincides with the initiation of Sry
expression, which is first detected in the gonad between
10.5 and 10.8 dpc (Hacker et al., 1995; Bullejos and Koop-
man, 2001), suggesting that proliferation within this period
is an early part of the initiation of the male pathway by Sry.
Based on expression of Sertoli cell markers Sox9 and
Mis, proliferation inhibition during this window either de-
creased or blocked differentiation of Sertoli cells, implying
that proliferation within this critical period occurs in Sertoli
precursors. This critical period occurs slightly earlier than a
male-specific increase in proliferation is detected at the
coelomic surface of the XY gonad (between 11.2 and 11.8
dpc; Schmahl et al., 2000). This timing suggests that de-
tectable proliferation differences between XY and XX go-
nads may be secondary to earlier stages of proliferation in
the XY gonad. Despite the fact that proliferation rates are
not noticeably different in males and females before 11.2
dpc, BrdU pulse chase studies demonstrate that precursors
of Sertoli cells proliferate in the male throughout this stage
(Fig. 4; Schmahl et al., 2000). Also, the earliest signs of
Sertoli differentiation, such as cell hypertrophy and the
upregulation of Sox9, occur by 11.0 dpc (Magre et al., 1980;
Bullejos and Koopman, 2001), suggesting that the establish-
ment of this lineage begins earlier, during the critical stage
of proliferation.
How does cell proliferation act to establish the male
pathway?
It is not yet clear how proliferation is involved in the
establishment of the male pathway. Much evidence argues
against Mittwoch’s original idea (Mittwoch, 1969) that an
increase in size alone determines maleness, but the impor-
tance of proliferation in the male pathway suggests that we
should consider a number of possibilities that link prolifer-
ation with the molecular control of Sertoli cell specification
or lineage expansion downstream of Sry.
Although Sry contains an HMG-type DNA binding do-
main, its DNA targets are still unknown. There is evidence
that HMG-type DNA binding domains may be involved in
establishing chromatin domains (Ferrari et al., 1992; Suda et
al., 1996). It has been suggested that a mitotic cell division
is required to reset chromatin domain architecture (Holtzer
et al., 1975, 1983), providing a possible link between the
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function of Sry and cell proliferation. In Drosophila, the
link between cell division and gene expression is dependent
on the polycomb group genes, which are responsible for
local compaction of chromatin domains at specific sites
(Weigmann and Lehner, 1995). Interestingly, deletion of a
mouse homologue of these genes (M33) results in decreased
gonadal growth and male-to-female sex reversal (Katoh-
Fukui et al., 1998), suggesting a role for both chromatin
domains and proliferation in the determination of the male
pathway.
In this study, inhibition of proliferation during the critical
period eliminated Sertoli cells, a cell type known to have
critical roles in testis development. At early stages, Sertoli cell
precursors express Sry, which appears to act through this cell
type to divert the gonad from the ovarian to the testis pathway
(reviewed in Burgoyne and Palmer, 1993; Albrecht and Eicher,
2001). Asymmetric division has been shown to control fate
specification in a number of systems (Horvitz and Herskowitz,
1992). It is possible that cell division in the early gonad is
required to allocate cellular components asymmetrically in the
process of Sertoli lineage specification in the XY gonad. Thus,
blocking this division could prevent the differentiation of Ser-
toli cells. Another function of cell proliferation during organo-
genesis is to increase the number of precursors for terminally
differentiated cell types. Multiple lines of evidence indicate
that a minimum number (threshold) of Sry-expressing pre-
Sertoli cells is necessary to drive sex determination: (1) Anal-
ysis of XX-XY chimeras in mice and humans indicate that, if
more than 30% of the cells of the gonad are XY, XY cells
become Sertoli cells and testis development proceeds; whereas
if less than 20% of the cells are XY, ovary differentiation is
initiated (reviewed in Burgoyne and Palmer, 1993). (2) In
humans, the translocation of Sry onto a preferentially inacti-
vated X chromosome is expected to result in fewer cells that
are capable of expressing Sry (and forming Sertoli cells). These
individuals do not form testes, but instead develop ovaries or
gonads with mixed ovarian and testis tissue, despite the pres-
ence of a functional Sry gene (Fechner et al., 1994; Kusz et al.,
1999). (3) An increase in the proliferation of a population that
contains Sertoli cell precursors is downstream of Sry and is one
of the earliest morphological differences between the sexes
(Schmahl et al., 2000). In the context of previous work, our
data suggests that an early function of proliferation in the XY
gonad may be to increase the number of Sertoli cell precursors
to a number above the threshold necessary to direct testis
determination. The present results don’t distinguish between
these possible roles of cell proliferation in the gonad, but
strongly indicate that proliferation is a necessary part of the
male pathway.
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